Eli Lilly's Retatrutide Shows Record Weight Loss in Phase 3 Trial
Eli Lilly's triple-hormone injection retatrutide achieved record weight loss results in an 80-week Phase 3 obesity trial, outperforming existing drugs and approaching outcomes of bariatric surgery. The study, presented at a medical conference, showed participants losing up to 24% of body weight on average. Retatrutide targets three gut hormones (GIP, GLP-1, and glucagon) to suppress appetite and boost metabolism. The drug could become a leading treatment for obesity if approved, intensifying competition with Novo Nordisk's Wegovy and Ozempic. Eli Lilly plans to seek regulatory approval later this year.
Key facts
- Retatrutide is a triple-hormone injection developed by Eli Lilly.
- The Phase 3 trial lasted 80 weeks.
- Participants lost up to 24% of body weight on average.
- The drug targets GIP, GLP-1, and glucagon receptors.
- Results approached outcomes of bariatric surgery.
- Eli Lilly plans to seek regulatory approval later this year.
- The drug outperformed existing weight loss medications.
- Competitors include Novo Nordisk's Wegovy and Ozempic.
Entities
Institutions
- Eli Lilly
- Novo Nordisk
Sources
- Quartz —